Lili Xia

Lili Xia

Auto-generated profile, based on publicly available information

Lili Xia

Materdicine Lab, School of Life Sciences Shanghai University Shanghai China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2026 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
HRHongze Ren
Hongze Ren
QWQingying Wu
Qingying Wu
WYWei Yang
Wei Yang
ZTZhengqi Tang
Zhengqi Tang
LXLili Xia
Lili Xia
Yu ChenYu Chen
Yu Chen

11 September 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
HRHongze Ren
Hongze Ren
QWQingying Wu
Qingying Wu
WYWei Yang
Wei Yang
ZTZhengqi Tang
Zhengqi Tang
LXLili Xia
Lili Xia
Yu ChenYu Chen
Yu Chen

16 October 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
JCJiajun Chen
Jiajun Chen
XLXiangqi Li
Xiangqi Li
JDJiali Deng
Jiali Deng
YWYing Wang
Ying Wang
WFWei Feng
Wei Feng
BHBingcang Huang
Bingcang Huang
Ischemic stroke (IS), caused by cerebral blood vessel occlusion, leads to ischemia, hypoxia, and irreversible brain tissue damage. Current treatments primarily rely on thrombolytic agents like alteplase, urokinase, and streptokinase for rapid reperfusion. However, these therapies are limited by narrow therapeutic windows, rapid clearance, poor blood‐brain barrier (BBB) penetration, off‐target effects, and the complex ischemic microenvironment. These have led to increased interest in nanomaterial‐based platforms to improve the precision and efficacy of IS treatment. The IS microenvironment, characterized by oxidative stress, inflammation, ionic imbalance, acidosis, and BBB disruption, provides valuable cues for designing responsive nanomaterials. Nanomaterials engineered to respond to reactive oxygen species, pH, enzymes, light, ultrasound, or magnetic fields can enable targeted drug delivery, controlled release, and multi‐modal interventions, enhancing therapeutic precision. This review discusses the IS microenvironment, limitations of traditional therapies, recent advances in intelligent nanomaterials for IS treatment, and the major barriers that currently limit clinical translation.